{{medical}}
{{Drugbox
| verifiedrevid = 456682333
| IUPAC_name = N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine
| image = Altretamine Structural Formulae V.1.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|altretamine}}
| MedlinePlus = a601200
| pregnancy_US = D
| legal_US = Rx-only
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| protein_bound = 94%
| elimination_half-life = 4.7-10.2小时

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 645-05-6
| ATC_prefix = L01
| ATC_suffix = XX03
| PubChem = 2123
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00488
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2038
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Q8BIH59O7H
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02841
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 24564
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1455

<!--Chemical data-->
| C=9 | H=18 | N=6 
| molecular_weight = 210.28 g/mol
| smiles = n1c(nc(nc1N(C)C)N(C)C)N(C)C
| InChI = 1/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3
| InChIKey = UUVWYPNAQBNQJQ-UHFFFAOYAJ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UUVWYPNAQBNQJQ-UHFFFAOYSA-N
}}

'''六甲蜜胺'''（{{lang-en|'''Altretamine'''}}）是一种[[化疗|化疗]]药物，属[[三聚氰胺|三聚氰胺]]（蜜胺）的[[衍生物|衍生物]]。它在1990年由[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）批准以'''Hexalen'''的商品名上市。

==用途==
六甲蜜胺主要用于治疗[[卵巢癌|卵巢癌]]。它不属于一线药物，<ref name="pmid12586589">{{cite journal |author=Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A |title=Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study |journal=Gynecol. Oncol. |volume=88 |issue=2 |pages=118–22 |year=2003 |pmid=12586589 |doi=10.1016/S0090-8258(02)00103-8}}</ref> 但其低毒性使其常用于[[顺铂|顺铂]]或其他[[烷化剂|烷化剂]]治疗后仍反复发作或对治疗无应答的卵巢癌，<ref>{{Cite journal | last1 = Markman | first1 = M. | last2 = Blessing | first2 = J. A. | last3 = Moore | first3 = D. | last4 = Ball | first4 = H. | last5 = Lentz | first5 = S. S. | title = Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial | doi = 10.1006/gyno.1998.5016 | journal = Gynecologic Oncology | volume = 69 | issue = 3 | pages = 226–229 | year = 1998 | pmid = 9648592 | pmc = }}</ref> 尤其是晚期[[癌症|癌症]]的[[姑息疗法|姑息疗法]]。<ref name="pmid11302345">{{cite journal |author=Malik IA |title=Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer |journal=Jpn. J. Clin. Oncol. |volume=31 |issue=2 |pages=69–73 |year=2001 |pmid=11302345 |doi=10.1093/jjco/hye012}}</ref><ref name="pmid14751188">{{cite journal |author=Chan JK, Loizzi V, Manetta A, Berman ML |title=Oral altretamine used as salvage therapy in recurrent ovarian cancer |journal=Gynecol. Oncol. |volume=92 |issue=1 |pages=368–71 |year=2004 |pmid=14751188 |doi=10.1016/j.ygyno.2003.09.017}}</ref>

六甲蜜胺也可用于治疗其他癌症（一般与其他化疗药物合用），如[[支气管肺癌|支气管肺癌]]、[[乳腺癌|乳腺癌]]、[[恶性淋巴瘤|恶性淋巴瘤]]、[[子宫内膜癌|子宫内膜癌]]、[[慢性粒细胞白血病|慢性粒细胞白血病]]等。<ref name="pku">{{cite book | title=抗肿瘤药物手册 | publisher=北京大学医学出版社 | author=孙燕 | year=2006 | location=北京 | isbn=978-7-811-16205-9}}</ref>

==作用机理==
六甲蜜胺的具体作用机理仍不是特别清楚——一般来说将它列为[[烷化剂|烷化剂]]，如[[MeSH|MeSH]]的分类；ATC则将其列为“其它抗肿瘤药”。<ref name="pmid7656502">{{cite journal |author=Damia G, D'Incalci M |title=Clinical pharmacokinetics of altretamine |journal=Clinical pharmacokinetics |volume=28 |issue=6 |pages=439–48 |year=1995 |pmid=7656502 |doi=10.2165/00003088-199528060-00002}}</ref>

目前较为普遍接受的说法是六甲蜜胺的其中一些分解产物起到了类似烷化剂的抗癌作用。口服六甲蜜胺后，[[肝脏|肝脏]]中的[[细胞色素P450|细胞色素P450]]会催化其进行[[氧化|氧化]]与''N''-[[去甲基化|去甲基化]]，生成活性产物''N''-(甲基羟基)三聚氰胺（如三甲密醇，如下圖中的 Carbinolamine metabolite），<ref>{{Cite journal | last1 = Coley | first1 = H. M. | title = N-(Hydroxymethyl) melamines | journal = General pharmacology | volume = 28 | issue = 2 | pages = 177–182 | year = 1997 | pmid = 9013191 }}</ref> <ref name=Foye>{{Cite book | author =Thomas L. Lemke, David A. Williams | title =Foye's Principles of Medicinal Chemistry | location = USA |chapter=Cancer and Chemotherapy| publisher = LWW| date = 2012 | pages = 1199-1226 | ISBN = 978-1609133450 | accessdate = 2017-05-29  | language = en }} </ref>后者在细胞内进一步脱甲基生成[[甲醛|甲醛]]、甲醇胺、[[亚胺|亚胺]]離子（圖中的 Reactive iminium ion ）等中间体<ref name="Foye" />。这些小分子能够与[[DNA|DNA]]或[[蛋白質|蛋白質]]反应生成[[共价键|共价键]]，引起DNA的烷基化、双链间交联及与[[蛋白质|蛋白质]]间的交联，从而损害DNA<ref name="Foye" />，抑制[[DNA复制|DNA的复制]]和[[转录|转录]]，使癌细胞死亡。<ref>{{cite book | author = Williams, David H.; Lemke, Thomas L.; Foye, William O. | title = Foye's principles of medicinal chemistry | publisher = Lippincott Williams & Wilkins | location = Hagerstwon, MD | year = 2008 | pages =1162 | isbn = 0-7817-6879-9 | oclc = | doi = | url = http://books.google.com/books?id=R0W1ErpsQpkC&lpg=PA1010&dq=piperoxan%20anthistamine&pg=PA1010#v=onepage&q&f=false}}</ref>[[File:_Altretamine_mechanism.svg|thumb]]


也有研究认为六甲蜜胺是一种[[二氢叶酸还原酶抑制剂|二氢叶酸还原酶抑制剂]]，通过抑制[[二氢叶酸还原酶|二氢叶酸还原酶]]起到[[抗代谢物|抗代谢物]]的作用，阻碍癌细胞的DNA、[[RNA|RNA]]与蛋白质合成。主要支持的论据是六甲蜜胺与烷化剂无[[交叉抗药性|交叉抗药性]]。

由于六甲蜜胺极难溶于水，它只能通过口服给药且[[生物利用度|生物利用度]]较低，这因此限制了它在临床上的进一步应用。<ref>{{Cite journal | last1 = Damia | first1 = G. | last2 = d'Incalci | first2 = M. | title = Clinical pharmacokinetics of altretamine | journal = Clinical pharmacokinetics | volume = 28 | issue = 6 | pages = 439–448 | year = 1995 | pmid = 7656502 }}</ref>

==不良反应==
常见[[副作用|副作用]]包括[[恶心|恶心]]、[[呕吐|呕吐]]、[[腹泻|腹泻]]、[[周围神经病|周围神经病]]及[[骨髓抑制|骨髓抑制]]等。<ref name="gale" /> 其中肠胃和[[神经毒性|神经毒性]]是剂量限制性毒性，可分别通过服用[[止吐剂|止吐剂]]及与[[维生素B6|维生素B<sub>6</sub>]]合用来缓解；<ref name="pku" /> 但后者可能会显著降低六甲蜜胺/[[顺铂|顺铂]]联合化疗的效果。<ref>{{Cite journal | last1 = Wiernik | first1 = P. H. | last2 = Yeap | first2 = B. | last3 = Vogl | first3 = S. E. | last4 = Kaplan | first4 = B. H. | last5 = Comis | first5 = R. L. | last6 = Falkson | first6 = G. | last7 = Davis | first7 = T. E. | last8 = Fazzini | first8 = E. | last9 = Cheuvart | first9 = B. | title = Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: A study of the Eastern Cooperative Oncology Group | journal = Cancer investigation | volume = 10 | issue = 1 | pages = 1–9 | year = 1992 | pmid = 1735009 }}</ref> 骨髓抑制则较轻，一般见于给药后3~4周，停药后1周即可恢复。<ref name="pku" />

[[单胺氧化酶抑制剂|单胺氧化酶抑制剂]]（MAOI）与六甲蜜胺合用会引起严重的[[直立性低血压|直立性低血压]]；[[西咪替丁|西咪替丁]]则可增加此药的[[生物半衰期|生物半衰期]]和[[毒性|毒性]]。<ref name="gale">{{Cite book|last=Thackery |first=Ellen |title=The Gale Encyclopedia of Cancer: A-K |publisher=Thomson Gale |location=Detroit |year=2002 |page=41-42 |isbn=0-7876-5610-0}}</ref>

六甲蜜胺具有弱[[致突变性|致突变性]]。<ref>{{Cite journal | last1 = Ashby | first1 = J. | last2 = Callander | first2 = R. D. | last3 = Rose | first3 = F. L. | title = Weak mutagenicity to Salmonella of the formaldehyde-releasing anti-tumour agent hexamethylmelamine | journal = Mutation research | volume = 142 | issue = 3 | pages = 121–125 | year = 1985 | pmid = 3919288 }}</ref>

==另见==
* [[曲他胺|曲他胺]]
* [[三聚氰胺|三聚氰胺]]

==参考资料==
{{reflist|2}}

{{化疗药物}}

[[Category:三嗪|Category:三嗪]]
[[Category:DNA复制抑制剂|Category:DNA复制抑制剂]]
[[Category:罕用药|Category:罕用药]]